


Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	<b>Application Number</b>	10/693,047	
	<b>Filing Date</b>	October 24, 2003	
	<b>First Named Inventor</b>	Wouter E. Roorda et al.	
	<b>Group Art Unit</b>	1615	
	<b>Examiner Name</b>	Unassigned	
<b>Total Number of Pages in This Submission (excluding references)</b>	8	<b>Attorney Docket No.</b>	50623.349

## ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Deposit Account Authorization 07-1850 <input checked="" type="checkbox"/> Postage Paid Return Postcard <input type="checkbox"/> Response to Office Action <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Petition for Extension of Time (___ month) (in duplicate) <input type="checkbox"/> Amendment Transmittal Letter (in duplicate) <input checked="" type="checkbox"/> Information Disclosure Statement with Form PTO-1449 and 60 References <input type="checkbox"/> Request for Continued Examination (RCE) Transmittal <input type="checkbox"/> Express Mail Label No. <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Submission of Formal Drawings (in duplicate) <input type="checkbox"/> Other Enclosure(s) (please identify below):		
<table border="1"> <tr> <td>Remarks</td> <td></td> </tr> </table>			Remarks	
Remarks				

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Squire, Sanders & Dempsey L.L.P. Paul J. Meyer, Jr., Reg. No. 47,791
Signature	
Date	February 20, 2004

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

Typed or printed name	Dilora Haddad		
Signature		Date	February 20, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Examiner: Unassigned

Wouter E. Roorda et al.

Serial No. 10/693,047

Art Unit: 1615

Filed: October 24, 2003

Title: Permeabilizing reagents to increase drug delivery and a method of local delivery

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §§1.97-1.98**

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. *See*, 1276 Off. Gaz. Pat. Office 55. Since this patent application was filed after June 30, 2003, Applicants have not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited foreign patent documents and non-patent literature have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.


The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: February 20, 2004

SQUIRE, SANDERS & DEMPSEY L.L.P.  
One Maritime Plaza, Suite 300  
San Francisco, CA 94111  
Telephone (415) 954-0200  
Facsimile (415) 393-9887

Respectfully submitted,



Paul J. Meyer, Jr.  
Attorney for Applicants  
Reg. No. 47,791

<b>FORM PTO-1449 (Modified)</b>		US DEPARTMENT OF COMMERCE		Docket No.		Application No.	
Approved for use through 10/31/2002		US Patent and Trademark Office		50623.349		10/693,047	
<b>INFORMATION DISCLOSURE CITATION</b> <b>in an Application</b> (Use several sheets if necessary)				Applicant			
				Wouter E. Roorda et al.			
				Filing Date		Group Art Unit	
				October 24, 2003		1615	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	2,072,303	3/2/37	Herrmann et al.	128	335.5	
	A2	4,977,901	12/18/90	Ofstead	128	772	
	A3	5,021,044	6/4/91	Sharkawy	604	53	
	A4	5,268,164	12/7/93	Kozarich et al.	424	9	
	A5	5,328,471	7/12/94	Slepian	604	101	
	A6	5,464,650	11/7/95	Berg et al.	427	2.30	
	A7	5,578,073	11/26/96	Haimovich et al.	623	1	
	A8	5,605,696	2/25/97	Eury et al.	424	423	
	A9	5,628,730	5/13/97	Shapland et al.	604	21	
	A10	5,667,767	9/16/97	Greff et al.	424	9.411	
	A11	5,670,558	9/23/97	Onishi et al.	523	112	
	A12	5,686,416	11/11/97	Kozarich et al.	514	15	
	A13	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A14	5,716,981	2/10/98	Hunter et al.	514	449	
	A15	5,800,392	9/1/98	Racchini	604	96	
	A16	5,824,049	10/20/98	Ragheb et al.	623	1	
	A17	5,830,178	11/3/98	Jones et al.	604	49	
	A18	5,830,879	11/3/98	Isner	514	44	
	A19	5,837,313	11/17/98	Ding et al.	427	2.21	
	A20	5,843,172	12/1/98	Yan	623	1	
	A21	5,851,508	12/22/98	Greff et al.	424	9.411	
	A22	5,865,814	2/2/99	Tuch	604	265	
	A23	5,873,904	2/23/99	Ragheb et al.	623	1	
	A24	5,971,954	10/26/99	Conway et al.	604	96	
	A25	5,980,928	11/9/99	Terry	424	427	
	A26	5,980,972	11/9/99	Ding	427	2.24	
	A27	6,010,530	1/4/00	Goicoechea	623	1	

	A28	6,015,541	1/18/00	Greff et al.	424	1.25		
	A29	6,096,070	8/1/00	Ragheb et al.	623	1		
	A30	6,153,252	11/28/00	Hossainy et al.	427	2.3		
	A31	6,165,212	12/26/00	Dereume et al.	623	1.13		
FOREIGN PATENT DOCUMENTS								
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
	B1	WO 91/12846	9/5/91	PCT				
	B2	EP 0 665 023	8/2/95	European				
	B3	WO 97/45105	12/4/97	PCT				
	B4	WO 99/63981	12/16/99	PCT				
	B5	EP 0 970 711	1/12/00	European				
	B6	WO 00/12147	3/9/00	PCT				
	B7	WO 00/64506	11/2/00	PCT				
	B8	WO 01/01890	1/11/01	PCT				
	B9	WO 01/45763	6/28/01	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
	C1	Alt et al., <i>Inhibition of Neointima Formation After Experimental Coronary Artery Stenting: A New Biodegradable Stent Coating Releasing Hirudin and the Prostacyclin Analogue Iloprost</i> , Circulation March 28, 2000; 101:1453-1458.						
	C2	Baldus et al., <i>Treatment Of Aortocoronary Vein Graft Lesions With Membrane-Covered Stents</i> , Circulation, 2000; 102:2024-2027.						
	C3	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> ; JACC Vol. 13, No. 2, February 1989:252A (Abstract).						
	C4	Christodoulos Stefanadis et al., <i>Stents Covered By Autologous Venous Grafts: Feasibility And Immediate And Long-Term Results</i> , American Heart Journal, March 2000, Vol. 139, No. 3, pp. 437-445.						
	C5	de Scheerder et al., <i>Local Methylprednisolone Inhibition Of Foreign Body Response To Coated Intracoronary Stents</i> , Coronary Artery Disease, February 1996, Vol. 7 No. 2, pp. 161-166.						
	C6	Forrester, et al., <i>A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies</i> , Journal of the American College of Cardiology, March 1, 1991, Vol. 17, No. 3, pp 758-769.						
	C7	Hurni et al., <i>Permeability Enhancement in Caco-2 Cell Monolayers by Sodium Salicylate and Sodium Taurodihydrofusidate: Assessment of Effect-Reversibility and Imaging of Transepithelial Transport Routes by Confocal Laser Scanning Microscopy</i> , The Journal of Pharmacology and Experimental Therapeutics Vol. 267, No. 2, pp. 942-950 (1993).						
	C8	Kasirajan et al., <i>Delayed onset of ascending paralysis after thoracic aortic stent graft deployment</i> , Journal of Vascular Surgery, Jan. 2000, Vol. 31, No. 1, Part 1, pp. 196-199.						
	C9	Matsumaru et al., <i>Emboic Materials For Endovascular Treatment of Cerebral Lesions</i> ; J. Biomater. Sci. Polymer Edn, Vol. 8, No. 7 (1997), pp. 555-569.						
	C10	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6)(1985), pp. 2490-2498.						

C11	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol. (1997), pp. 157-162.
C12	Monnier et al., <i>The Use Of The Covered Wallstent For The Palliative Treatment Of Inoperable Tracheobronchial Cancers</i> , Chest, 1996; 110:5:1161-1168.
C13	Nobuyoshi et al., <i>Restenosis After Percutaneous Transluminal Coronary Angioplast: Pathologic Observations in 20 Patients</i> , Journal of the American College of Cardiology, February 1991, Vol. 17, No. 2, pp 433-439.
C14	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , American Heart Journal (Dec. 1998), pp. 1081-1087.
C15	Park et al., <i>Anti-inflammatory Stent Coatings: Dexamethasone And Related Compounds</i> , Semin. Intervent. Cardiol. 1998; 3:191-195.
C16	Rechavia et al., <i>Biocompatibility of Polyurethane-Coated Stents: Tissue and Vascular Aspects</i> , Catheterization and Cardiovascular Diagnosis 45:202-207 (1998).
C17	Schellhammer et al., <i>Polyethylene Terephthalate And Polyurethane Coatings For Endovascular Stents: Preliminary Results In Canine Experimental Arteriovenous Fistulas</i> , Radiology, April 1999, pp. 169-175.
C18	Shigeno, <i>Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).
C19	van Hoogdalem et al., <i>3-Amino-1-hydroxypropylidene-1, 1-diphosphonate (APD): A Novel Enhancer Of Rectal Cefoxitin Absorption In Rats</i> , J. Pharm. Pharmacol. 1989, 41:339-341.
C20	van Hoogdalem et al., <i>Rectal Absorption Enhancement of Cefoxitin and Desglycinamide Arginine Vasopressin by Sodium Tauro-24, 25-Dihydrofusidate in Conscious Rats</i> , The Journal of Pharmacology and Experimental Therapeutics 1989, Vol. 251, No. 2, pp. 741-744.
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	